Want to see SIBN full AI Analyst Report?
SIBN Stock Chart & Stats
$14.09
$0.02(0.14%)
At close: 4:00 PM EST
$14.09
$0.02(0.14%)
Day’s Range― - ―
52-Week Range$11.48 - $21.89
Previous CloseN/A
Volume50.81K
Average Volume (3M)648.60K
Market Cap
$778.77M
Enterprise Value$648.37M
Total Cash (Recent Filing)$144.68M
Total Debt (Recent Filing)$7.35M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding44,349,280
10 Day Avg. Volume524,959
30 Day Avg. Volume648,599
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda-108.26
Forecast
1Y Price Target
$22.50Price Target Upside59.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$230.50M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~79–80% gross margins indicate strong per-procedure unit economics and pricing power in SI joint implants. Durable high margins provide structural leverage to absorb ASP pressure, fund R&D and commercial expansion, and improve the path to operating profitability over the next several quarters.
Strong Liquidity / Low LeverageA sizable cash balance combined with very low leverage (debt-to-equity ~0.04) gives the company runway to fund launches, partner rollouts and HQ/instrument CapEx without near-term refinancing risk. This balance sheet strength supports execution across 2–6 months of product and commercial investments.
Robust Commercial AdoptionTwenty consecutive quarters of physician growth and rising revenue per territory show scalable sales productivity and durable surgeon adoption. A growing installed base and territory productivity underpin recurring per-procedure revenue and sustainable top-line expansion beyond near-term market fluctuations.
Bears Say
Ongoing GAAP Losses & Negative FCFDespite margin and revenue progress, persistent GAAP losses and negative free cash flow mean SI-BONE has not yet achieved self-funding operations. Continued deficits limit reinvestment flexibility and keep the company dependent on existing cash reserves until sustained positive FCF is achieved.
Near-Term CapEx And Cash VariabilityPlanned HQ buildout and elevated instrument/tray investment materially increase near-term cash outflows. These discretionary but necessary investments will pressure free cash flow timing and can delay reaching breakeven, making short-term liquidity management important despite strong cash balances.
Execution & ASP/Mix Risk From PartnershipsGrowth depends on phased partner rollouts and new product launches, creating timing and execution risk. Concurrent ASP/mix pressure (lower implants per case) could compress revenue per procedure, making margin and revenue outcomes sensitive to partner training, hospital adoption, and case mix shifts.
SI-Bone News
SIBN FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was $11.48 and its highest was $21.89 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is $778.77M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Aug 10, 2026 which is in 27 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on May 11, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.088.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.15.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,349,280 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 19.724%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in SIBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (59.69% Upside)
$22.50 (59.69% Upside)
Blogger Sentiment
Bullish
SIBN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 741.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $507.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.93%
12-Months-Change
Fundamentals
Return on Equity
-9.56%
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
SIBN Stock 12 Month Forecast
Average Price Target
$22.50
▲(59.69% Upside)
Technical Analysis
Ownership Overview
5.15% Insiders
26.49% Mutual Funds
46.01% Other Institutional Investors
10.46% Public Companies and
Individual Investors